Guar gum as a new antimicrobial peptide delivery system against diabetic foot ulcers Staphylococcus aureus isolates

Journal of Medical Microbiology

Volumn 65, Issue 10, 2016, Pages 1092-1099

  Santos, Raquel ^a,b   Gomes, Diana ^c   Macedo, Hermes ^a   Barros, Diogo ^d   Tibério, Catarina ^a   Veiga, Ana Salomé ^b   Tavares, Luís ^a   Castanho, Miguel ^b   Oliveira, Manuela ^a  

^a FACULDADE DE MEDICINA VETERINÁRIA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c INSTITUTO SUPERIOR DE PSICOLOGIA APLICADA   (Portugal)

^d UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

GUAR GUM; NISIN; ANTIINFECTIVE AGENT; DRUG CARRIER; GALACTAN; MANNAN; PLANT GUM;

ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DIABETIC FOOT; DRUG DELIVERY SYSTEM; HUMAN; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; BIOFILM; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PHYSIOLOGY; ULCER;

ANTI-INFECTIVE AGENTS; BIOFILMS; DIABETIC FOOT; DRUG CARRIERS; GALACTANS; HUMANS; MANNANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; NISIN; PLANT GUMS; STAPHYLOCOCCUS AUREUS; ULCER;

EID: 84992393717     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000329     Document Type: Article

References (45)

1. Abts,A.,Mavaro,A.,Stindt,J.,Bakkes,P.,Metzger,S.,Driessen,A.,Smits,S. & Schmitt,L. (2011). Easy and rapid purification of highly active nisin. Int J Pept 2011,175145.
2. Akhi,M. T.,Ghotaslou,R.,Memar,M. Y.,Asgharzadeh,M.,Varshochi,M.,Pirzadeh,T. & Alizadeh,N. (2016). Frequency of MRSA in diabetic foot infections. Int J Diab Dev Ctries,1-5.
3. An,S. Q. & Ryan,R. P. (2016). Combating chronic bacterial infections by manipulating cyclic nucleotide-regulated biofilm formation. Future Med Chem 8,949-961.
4. Armstrong,D. G.,Cohen,K.,Courric,S.,Bharara,M. & Marston,W. (2011). Diabetic foot ulcers and vascular insufficiency: our population has changed,but our methods have not. J Diabetes Sci Technol 5,1591-1595.
5. Batoni,G.,Maisetta,G. & Esin,S. (2016). Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. Biochim Biophys Acta 1858,1044-1060.
6. Ceri,H.,Olson,M. E.,Stremick,C.,Read,R. R.,Morck,D. & Buret,A. (1999). The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 37,1771-1776.
7. Cleveland,J.,Montville,T. J.,Nes,I. F. & Chikindas,M. L. (2001). Bacteriocins: safe,natural antimicrobials for food preservation. Int J Food Microbiol 71,1-20.
8. CLSI (2013). Performance Standards for Antimicrobial Susceptibility Testing; Approved Standard. 23rd Informational Supplement M100-S23. Wayne,PA: Clinical and Laboratory Standards Institute.
9. Dang,C. N.,Prasad,Y. D.,Boulton,A. J. & Jude,E. B. (2003). Methicillin-resistant Staphylococcus aureus in the diabetic foot clinic: a worsening problem. Diabet Med 20,159-161.
10. Dickschat,J. S. (2010). Quorum sensing and bacterial biofilms. Nat Prod Rep 27,343-369.
11. ECDC (2015). Annual Report of the European Antimicrobial Resistance Surveillance Network. Antimicrobial Resistance Surveillance in Europe 2014. Stockholm,Sweden: European Centre for Disease Prevention and Control.
12. EFSA (2006). The use of nisin (E 234) as a food additive. EFSA Journal 314,1-16.
13. French,G. L. (2006). Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin. J Antimicrob Chemother 58,1107-1117.
14. Gharsallaoui,A.,Oulahal,N.,Joly,C. & Degraeve,P. (2016). Nisin as a food preservative: part 1: physicochemical properties,antimicrobial activity,and main uses. Crit Rev Food Sci Nutr 56,1262-1274.
15. Hancock,R. E. & Sahl,H. G. (2006). Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24,1551-1557.
16. Jeffcoate,W. J. & Harding,K. G. (2003). Diabetic foot ulcers. Lancet 361,1545-1551.
17. Jenkins,A.,Diep,B. A.,Mai,T. T.,Vo,N. H.,Warrener,P.,Suzich,J.,Stover,C. K. & Sellman,B. R. (2015). Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. MBio 6,e02272-14.
18. Kandemir,O.,Akbay,E.,Sahin,E.,Milcan,A. & Gen,R. (2007). Risk factors for infection of the diabetic foot with multi-antibiotic resistant microorganisms. J Infect 54,439-445.
19. Kaplan,J. B. (2011). Antibiotic-induced biofilm formation. Int J Artif Organs 34,737-751.
20. Kirikae,T.,Hirata,M.,Yamasu,H.,Kirikae,F.,Tamura,H.,Kayama,F.,Nakatsuka,K.,Yokochi,T. & Nakano,M. (1998). Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infect Immun 66,1861-1868.
21. Lewis,K. (2013). Platforms for antibiotic discovery. Nat Rev Drug Discov 12,371-387.
22. Lipsky,B. A.,Berendt,A. R.,Deery,H. G.,Embil,J. M.,Joseph,W. S.,Karchmer,A. W.,LeFrock,J. L.,Lew,D. P.,Mader,J. T. & other authors (2004). Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39,885-910.
23. Magiorakos,A. P.,Srinivasan,A.,Carey,R. B.,Carmeli,Y.,Falagas,M. E.,Giske,C. G.,Harbarth,S.,Hindler,J. F.,Kahlmeter,G. & other authors (2012). Multidrug-resistant,extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18,268-281.
24. McAuliffe,O.,Ross,R. P. & Hill,C. (2001). Lantibiotics: structure,biosynthesis and mode of action. FEMS Microbiol Rev 25,285-308.
25. Mendes,J. J.,Marques-Costa,A.,Vilela,C.,Neves,J.,Candeias,N.,Cavaco-Silva,P. & Melo-Cristino,J. (2012). Clinical and bacteriological survey of diabetic foot infections in Lisbon. Diabetes Res Clin Pract 95,153-161.
26. Mendes,J. J.,Leandro,C.,Mottola,C.,Barbosa,R.,Silva,F. A.,Oliveira,M.,Vilela,C. L.,Melo-Cristino,J.,Górski,A. & other authors (2014). In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms causing diabetic foot infections. J Med Microbiol 63,1055-1065.
27. Mohammad,H.,Thangamani,S. & Seleem,M. (2015). Antimicrobial peptides and peptidomimetics - potent therapeutic allies for staphylococcal infections. Curr Pharm Des 21,2073-2088.
28. Mottola,C.,Mendes,J. J.,Cristino,J. M.,Cavaco-Silva,P.,Tavares,L. & Oliveira,M. (2016a). Polymicrobial biofilms by diabetic foot clinical isolates. Folia Microbiol 61,35-43.
29. Mottola,C.,Semedo-Lemsaddek,T.,Mendes,J. J.,Melo-Cristino,J.,Tavares,L.,Cavaco-Silva,P. & Oliveira,M. (2016b). Molecular typing,virulence traits and antimicrobial resistance of diabetic foot staphylococci. J Biomed Sci 23,33.
30. O’Driscoll,N. H.,Labovitiadi,O.,Cushnie,T. P.,Matthews,K. H.,Mercer,D. K. & Lamb,A. J. (2013). Production and evaluation of an antimicrobial peptide-containing wafer formulation for topical application. Curr Microbiol 66,271-278.
31. Okuda,K.,Zendo,T.,Sugimoto,S.,Iwase,T.,Tajima,A.,Yamada,S.,Sonomoto,K. & Mizunoe,Y. (2013). Effects of bacteriocins on methicillin-resistant Staphylococcus aureus biofilm. Antimicrob Agents Chemother 57,5572-5579.
32. Overhage,J.,Campisano,A.,Bains,M.,Torfs,E. C.,Rehm,B. H. & Hancock,R. E. (2008). Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 76,4176-4182.
33. Pettit,R. K.,Weber,C. A.,Kean,M. J.,Hoffmann,H.,Pettit,G. R.,Tan,R.,Franks,K. S. & Horton,M. L. (2005). Microplate Alamar blue assay for Staphylococcus epidermidis biofilm susceptibility testing. Antimicrob Agents Chemother 49,2612-2617.
34. Reddy,K.,Mohan,G. K.,Satla,S. & Gaikwad,S. (2011). Natural polysaccharides: versatile excipients for controlled drug delivery systems. Asian J Pharm Sci 6,275-286.
35. Richard,J. L.,Sotto,A.,Jourdan,N.,Combescure,C.,Vannereau,D.,Rodier,M.,Lavigne,J. P. & Nîmes University Hospital Working Group on the Diabetic Foot (GP30) (2008). Risk factors and healing impact of multidrug-resistant bacteria in diabetic foot ulcers. Diabetes Metab 34,363-369.
36. Richard,J. L.,Sotto,A. & Lavigne,J. P. (2011). New insights in diabetic foot infection. World J Diabetes 2,24-32.
37. Roglic,G. (2016). WHO global report on diabetes: a summary. Int J Non-Commun Dis 1,3.
38. Rosenfeld,Y.,Papo,N. & Shai,Y. (2006). Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. peptide properties and plausible modes of action. J Biol Chem 281,1636-1643.
39. Stanaway,S.,Johnson,D.,Moulik,P. & Gill,G. (2007). Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. Diabetes Res Clin Pract 75,47-50.
40. Stewart,P. S. & Costerton,J. W. (2001). Antibiotic resistance of bacteria in biofilms. Lancet 358,135-138.
41. Strempel,N.,Strehmel,J. & Overhage,J. (2015). Potential application of antimicrobial peptides in the treatment of bacterial biofilm infections. Curr Pharm Des 21,67-84.
42. Thombare,N.,Jha,U.,Mishra,S. & Siddiqui,M. Z. (2016). Guar gum as a promising starting material for diverse applications: a review. Int J Biol Macromol 88,361-372.
43. Vuorisalo,S.,Venermo,M. & Lepäntalo,M. (2009). Treatment of diabetic foot ulcers. J Cardiovasc Surg 50,275-291.
44. Wiegand,I.,Hilpert,K. & Hancock,R. E. (2008). Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3,163-175.
45. Zasloff,M. (2002). Antimicrobial peptides of multicellular organisms. Nature 415,389-395.